Analysis for JPMorgan Equity Premium Income ETF
Analysis summary
JPMorgan Equity Premium Income ETF (JEPI) currently has a total score of 49 points, placing it in the neutral range. The score is made up of Performance (31), Stability (81) and Trend (47). The profile is clearly uneven: Stability stands out while Performance lags.
Performance scores 31 points (weak). Least weak metric: 1Y return at -0.1 %. Main drag: 5Y return at 5.5 %. This points to a sharper upswing more recently.
Stability scores 81 points (very strong). Key strength: volatility (365d, annualized) at 13.6 %. Main drag: CAGR/drawdown ratio at 0.05. Higher Stability points are better and typically reflect calmer swings and smaller drawdowns—but prices can still fall.
Trend scores 47 points (neutral). Key strength: trend strength at 0.85. Weaker metric: 12M momentum at -1.4 %.
Overall, the picture is mixed: Stability does the heavy lifting while Performance holds the score back. On a metric level, volatility (365d, annualized) stands out, while CAGR/drawdown ratio is the main weak spot.
(Historical evaluation, not investment advice.)
Metrics
Stability
FAQ
- What investor type does JPMorgan Equity Premium Income ETF fit best in FoxScore?
- JPMorgan Equity Premium Income ETF fits a more defensive investor type in FoxScore: stability is the strongest part of the profile. That points to comparatively smaller drawdowns and calmer swings versus the universe — but prices can still fall.
- How meaningful is the available history for JPMorgan Equity Premium Income ETF?
- JPMorgan Equity Premium Income ETF currently has about 5.7 years of price history since it started trading. This lets you judge how it behaved in its market phases since launch, but long-term conclusions across multiple cycles are naturally limited.
- What is FoxScore good for — and what is it not for?
- FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.